C

China National Accord Medicines Corp Ltd
SZSE:000028

Watchlist Manager
China National Accord Medicines Corp Ltd
SZSE:000028
Watchlist
Price: 24.8 CNY 0.45% Market Closed
Market Cap: ¥13.8B

P/E

12.2
Current
5%
Cheaper
vs 3-y average of 12.8

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
12.2
=
Market Cap
¥14.8B
/
Net Income
¥1.1B

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
12.2
=
Market Cap
¥14.8B
/
Net Income
¥1.1B

Valuation Scenarios

China National Accord Medicines Corp Ltd is trading below its 3-year average

If P/E returns to its 3-Year Average (12.8), the stock would be worth ¥26.06 (5% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-1%
Maximum Upside
+176%
Average Upside
81%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 12.2 ¥24.8
0%
3-Year Average 12.8 ¥26.06
+5%
5-Year Average 12 ¥24.56
-1%
Industry Average 33.5 ¥68.41
+176%
Country Average 29.6 ¥60.47
+144%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
¥14.8B
/
Jan 2026
¥1.1B
=
12.2
Current
¥14.8B
/
Dec 2026
¥1.2B
=
12.2
Forward
¥14.8B
/
Dec 2027
¥1.1B
=
13
Forward
¥14.8B
/
Dec 2028
¥1.2B
=
11.9
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Market Distribution

Lower than 82% of companies in China
Percentile
18th
Based on 5 557 companies
18th percentile
12.2
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

China National Accord Medicines Corp Ltd
Glance View

Market Cap
13.8B CNY
Industry
Health Care

China National Accord Medicines Corp Ltd, nestled within the bustling healthcare landscape of China, operates at the heart of the pharmaceutical distribution and retail sectors. Established with the goal of ensuring that essential medicines and healthcare services are accessible to the vast Chinese population, the company has built an extensive distribution network. This network efficiently links manufacturers with hospitals, clinics, and pharmacies, making certain that a myriad of pharmaceutical products reach their intended destinations. By leveraging a combination of logistical prowess and vast geographical coverage, the company adeptly navigates the complexities of supply chain management, underscoring its role as a critical player in China's healthcare infrastructure. Beyond distribution, China National Accord Medicines also capitalizes on the booming retail pharmaceuticals market through its chain of pharmacies. These retail outlets serve as direct points of sale to consumers, offering both prescription and over-the-counter medications, alongside health consultation services. This dual focus on both wholesale distribution and retail outlets enables the company to capture value across the supply chain, from manufacturer to end-user. The strategic alignment of its operations streamlines efficiency and generates revenue, sustaining its growth amid a fiercely competitive and rapidly evolving market. Through this integrated approach, the company solidifies its position as a crucial conduit in the delivery of healthcare solutions across China.

Intrinsic Value
73.5 CNY
Undervaluation 66%
Intrinsic Value
Price ¥24.8
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett